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Introduction
This historical approach to past CF research shows that the evidence for the mucus 
hydration view is slender and can be called into question as providing adequate proof. 
This approach also indicates that associated smooth muscle cell pathophysiology in 
CF has been overlooked but may prove to be the more productive hypothesis. Present 
views on the pathophysiology of cystic ϐibrotic lung function have drawn heavily on 
developments within the ϐield of intestinal secretion physiology, having assumed that 
the current paradigm of enterocyte secretion is, in almost all respects, the correct 
one for explaining how secretory diarrhoeal disease occurs. This model for secretion 
assumes that microbes and associated pathogens act on normally occurring ϐluid 
secretion from the enterocytes by pathologically enhancing chloride ion secretion, 
which in turn due to osmotic imbalance at the brush border compels the movement 
of ϐluid into the lumen. The enterocytes are purported to have a normally occurring 
chloride secretion mechanism, in addition to their undoubted ability to absorb ϐluid. 
Within the brush border of the enterocyte is a chloride channel (the cystic ϐibrosis 
transmembrane regulator or CFTR protein) that participates in a putative chloride 
secretion process. As the CFTR channel is defective in CFTR patients, for various reasons 
to be discussed, aspects of cystic ϐibrosis pathology became inextricably intertwined 
with small intestinal secretory diseases because of the common chloride ion channel in 
the affected lung and intestinal cell types. Particular weight was given to the possibility 
that heterozygote advantage in cystic ϐibrosis could be explained by a defective CFTR 
Summary
This review examines of the concept of a defective chloride channel in epithelial cells being a major cause 
of cystic fi brotic pathophysiology. The central concept of the defective chloride ion channel paradigm is that 
faulty CFTR protein or failed delivery of CFTR protein to the mucosal membrane of epithelial cells is the basis of 
cystic fi brosis. Defective placement or function of CFTR prevents hydration of bronchial mucus that is normally 
caused by epithelial cells; these are capable through chloride ion secretion of transporting fl uid to the mucosal 
surface. This concept relies heavily on a paradigm taken from intestinal physiology-namely that the intestinal 
epithelial cell secretes chloride ion and fl uid and that this has conferred heterozygote selective advantage in 
carriers of the cystic fi brosis gene. This present review examines the evidence for that hypothesis and assembles 
evidence from past studies that it is the smooth muscle cell that is of greater relevance. This review does not 
aim to provide an overview of current research into cystic fi brosis. The intention is to provide an overview of 
past research that led to the concept of a failure of epithelial cells to hydrate bronchial mucus because of 
compromised CFTR function. It is important to present all past evidence for aspects of the chloride secretion 
hypothesis and its associated heterozygote advantage concept so that the important evidential milestones can 
be re-assessed.
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channel. Since CFTR mediated chloride ion secretion is now assumed to underpin most 
forms of secretory diarrhoeal disease, a damaged CFTR channel would minimise or 
event prevent ϐluid secretion in intestinal diarrhoeal disease. The inability of CF gene 
heterozygotes to respond to speciϐic lethal pathogens would be consistent with this 
conferring an indisputable heterozygote advantage. This lack of ϐluid secretion was a 
satisfying explanation for the pulmonary pathophysiology of cystic ϐibrosis and also 
purported to explain how life threatening diarrhoeal disease could arise, particularly 
in a disease such as cholera.
The inference from small intestinal studies was that CFTR heterozygote intestinal 
tissue responded less to secretory stimuli and for that reason, a similar phenomenon 
might occur in cystic ϐibrotic patients. Translated into cystic ϐibrotic pathology, 
a failure to secrete ϐluid by analogous mucosal cells in the bronchial epithelium 
would mean a failure to lubricate bronchial mucus and more importantly make the 
viscous mucus more difϐicult to clear. This plus alteration in thickness of local ϐluid 
ϐilms would either reduce airϐlow or allow identical rates of air ϐlow to be achieved 
only through greater work done to overcome the resistance to ϐlow. The intellectual 
linkage between intestinal ϐluid secretion with production of sticky mucus in cystic 
ϐibrosis through the common theme of epithelial cell ϐluid secretion is an interesting 
example of a sub-hypothesis providing apparent support for a larger more inclusive 
hypothesis: a set of observations on cystic ϐibrotic tissues apparently adds substantial 
weight to the intestinal secretion paradigm. Falsiϐication of the cystic ϐibrotic sub-
hypothesis i.e. cessation of ϐluid secretion in the CF epithelium is not fatal to the larger 
intestinal secretion paradigm. However, the converse phenomenon of falsiϐication of 
the intestinal secretion model of chloride secretion through CFTR channels completely 
discredits current views on why the CF gene persists in the general population. This is 
not simply an intellectual question of academic interest only: it implies that the search 
for effective therapeutic agents for CF is not soundly based on correct conclusions 
about intestinal secretion. The difϐiculty for CF research is that the enterocyte 
secretion hypothesis for diarrhoeal disease is eminently challengeable [1]. If this is 
true, then several current directions within CF research are based on the faulty view 
that a very prominent aspect of CF pathology originates from the bronchial epithelial 
cells’ inability to secrete ϐluid. If the intestinal chloride ion secretion paradigm is false, 
it is evident that the causes of life threatening diarrhoeal disease lie outside of the 
epithelial cell. It is also probable that the focus on restoration of the defective chloride 
ion channel within epithelial tissues is unlikely to be a successful means of improving 
either secretion in the intestine or poor lung function in cystic ϐibrosis. A recent focus 
on gene delivery to respiratory epithelium to improve the defective CF channel had led 
to minor improvement in forced expiratory volume [2] and will continue to disappoint, 
if the central tenet of ϐluid secretion through chloride ion secretion is fundamentally 
wrong.
To explain why an alternative view is possible both for intestinal pathology in 
diarrhoeal disease and lung pathology in CF, it is necessary to describe what the 
intestinal chloride ion secretion model is and how it has overshadowed an older 
paradigm, based on vascular smooth muscle and not epithelial changes in disease 
states. It can then be seen that the smooth muscle model for intestinal secretion 
and rectiϐication by CFTR acting agents is applicable both to the respiratory and 
the intestinal tract. Not only will it be argued that smooth muscle constriction is an 
equally valid explanation for respiratory and intestinal pathology, it will be seen that 
the smooth muscle model is the better paradigm since it encompasses observations 
which have been left uncommented on in the secretion literature. Finally, recent work 
on CFTR enhancers is brieϐly reviewed and the suggestion noted that these latest 
compounds may also be acting on smooth muscle rather than epithelial cells.
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The enterocyte chloride ion secretion hypothesis as a basis for secretory 
diarrhoeal disease 
The current concept of ϐluid movement from the serosal side of the enterocyte 
into the lumen is essentially a biochemical intellectual construct since it relies on the 
internal energy from the epithelial cell to power ion ϐlows across the cell. The ion ϐlows 
themselves result from speciϐic carriers and channels that move ions in accordance 
with the formalism of enzyme kinetics as expected from the canonical foundations of 
biochemistry. Since prior to the enterocyte secretion view, the absorption of nutrients, 
sodium ion and ϐluid movement was so well explained by a cellular based view, it is 
perhaps not so surprising that an explanation for secretion of ϐluid should also have 
been based on a biochemical model. However, in this case, it is evident that biochemistry 
based models cannot transcend the short-comings of all explanations being cellular 
based and biochemical in origin. In this case, an explanation must be sought in the 
physical forces that cause mass transport, as is often the case in physiology. A more 
likely explanation is that of mass transport of ϐluid because of physical forces acting 
within tissues, although it must be acknowledged that the transported ϐluid should 
have the same composition as it had at its origin. A likely explanation for secretion of 
ϐluids of differing composition is that extruded ϐluid is operated on by the absorptive 
ion uptake mechanisms that are undoubtedly present in the enterocytes.
The purely biochemical model requires that chloride ion enters the enterocyte cell 
interior and leaves it through a mucosally sited chloride channel (Figure 1), assuming 
that the electrochemical gradient is correctly aligned for chloride ion extrusion into 
the lumen of the small intestine. The Na+/K+/2Cl- co-transporter (NKCC1 or NKCC2 
depending on the isoform) in the serosal border allows entry of chloride ion into the 
cell. This entry is energetically dependent on the ionic gradients for the three ions 
and it is likely that the sodium ion: potassium ion ATPase, Na+/K+ ATPase, provides a 
sodium ion gradient aligned for entry into the cell to pull chloride and potassium ions 
into the cell interior. Stoicheiometry dictates that two chloride ions enter the cell for 
every sodium ion returning via the triporter and hence the intracellular chloride ion 
concentration should build up. 
Given that the chloride ion should distribute across the mucosal membrane in 
accordance with the electrochemical gradient, the assumption is that at equilibrium, 
the tendency for chloride ion to enter the cell from the lumen because of the adverse 
chemical gradient is exactly balanced by the tendency for the chloride ion to exit 
through the CFTR channel. When chloride ions enter the enterocyte via the triporter, 
the assumption is that the concentration is slightly above equilibrium and chloride 
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ion will be extruded as electrochemical equilibrium is restored. From this, it can be 
seen that it is important for chloride ion extrusion that the cell membrane potential 
difference is maintained, a function attributed to serosal membrane potassium ion 
permeability. Given the presence of the biochemical machinery within the cell, routes 
for chloride ion translocation exist from the serosal to the mucosal surface of the 
enterocyte, together with appropriately balanced electrochemical forces that should 
allow chloride ion transmission to the mucosal surface. The extrusion of chloride ion 
together with sodium ion presumably through the paracellular pathways causes an 
accumulation of solute near the enterocyte brush border. This provides an osmotic 
pressure pulling ϐluid through the lateral spaces, ultimately from the sub-epithelial 
interstitial space. As a result, chloride ion and water move into the lumen. If this 
process can be enhanced by enterotoxins, then this would form the basis for enhanced 
intestinal secretion in secretory diarrhoeal disease. In the diagram, a receptor, R, for 
heat stable E. coli enterotoxin (STa) is present in the brush border. The enterocyte 
secretion view envisages that STa ϐits into the luminal receptor and elevates 
intracellular second messenger concentration, in this case cyclic GMP. This in turn, just 
as cAMP is thought to do for cholera toxin, acts via protein kinases on the CFTR channel 
causing it to become more permeable. Given no change in electrochemical gradients 
across the luminal membrane, it is possible that more chloride ions are extruded per 
unit electrochemical gradient and therefore more ϐluid is secreted.
While intellectually self-contained and satisfying within the constraints of in vitro 
work, the model does not survive challenge when confronted with observations from 
in vivo experiments. The canon of in vitro techniques used to measure 'secretion' such 
as isotope ϐluxes and electrical measurements are methodologically ϐlawed [3]. In vivo 
experiments not using permeable isotopes to measure ϐluid secretion indicate that i) E. 
coli STa cannot cause secretion [4] despite a wide spread expectation that it should and 
that ii) potassium channel blockers have no effect on secretion [5]. These and many 
other observations in the historical literature on the causes of secretory diarrhoea 
point to an alternative view that has been dormant in the secretion literature but 
can accommodate the data from the enterocyte secretion model whilst being itself a 
concept based on physical rather than chemical forces across the mucosa.
The intestinal arteriolar vasodilatation hypothesis as a basis for secretory 
diarrhoeal disease
An alternative model for ϐluid secretion is one that has repeatedly been put forward 
but has always been overshadowed by the epithelial cell ϐluid secretion model. This 
repeated intrusion of the physical forces model is often simply ignored. Its most 
convincing manifestation was as late as 1971 after the ϐinding that when small intestine 
was perfused in vivo with cholera toxin, the intestine secreted profusely. When that 
tissue was removed and made into everted sacs, the tissue did not secrete or rather 
could not secrete in vitro, presumably because of the absence of the necessary physical 
forces across the mucosa [6]. The physical model is presented (Figure 2) together with 
the biochemical model to facilitate comparison.
The ϐirst hypothesis (A) requires that enterotoxins cause enterocytes to secrete 
through mucosal chloride ion channels after exposure of the tissue to bacterial 
enterotoxins. The second hypothesis (B) relies on the fact that the villous capillary is 
not completely impermeable to ϐluid and that ϐluid moves into the interstitial space. It 
does so because of the Starling forces that exist across all capillaries in that an excess 
of intraluminal capillary pressure over interstitial ϐluid pressure pushes ϐluid into the 
sub-epithelial space and greater colloid osmotic pressure of the blood pulls ϐluid back 
into the capillary. A steady volume state is achieved when the loss of ϐluid into the 
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lumen is balanced by the tendency for interstitial ϐluid to move into the capillary. If 
there is a small net driving force for ϐluid movement into the lumen, this would be 
enhanced by increases in the tight junction widths. It should be remembered that 
an increase in tight junction width can also serve to promote ϐluid absorption if the 
luminal pressure, even if transiently, exceeds interstitial ϐluid pressure as it may do in 
the contracting intestine. If enterotoxins reduced ϐluid absorption, the model predicts 
increased seepage of ϐluid into the lumen since some of the exudate would presumably 
be reabsorbed by absorption. 
Compromise of absorption would undoubtedly lead to diarrhoea facilitated by 
seepage of interstitial ϐluid. Copious and life threatening diarrhoea at the rate that 
occurs during a cholera episode is likely to be caused by profound vasodilatation. It is 
a physiological and somewhat counterintuitive fact that capillary pressure increases 
if there is vaso-dilatation of the immediately preceding arteriole. The increase in 
vasodilatation causes the capillary pressure to rise from average values of 15 mmHg to 
whatever the arterial pressure is on the capillary side of the arteriole and may rise to 
40 mmHg or more. This increase in hydrostatic pressure forces ϐluid into the interstitial 
space and increases ϐluid secretion into the lumen by physical means. If accessory 
toxins increase epithelial and capillary endothelium paracellular pathways, as well as 
inhibit intestinal ϐluid absorption mechanisms, then this would lead to catastrophic 
ϐluid loss, essentially powered by the mechanical force of the heartbeat. It is unlikely 
that chemical reactions could match this degree of force or effect changes in interstitial 
volume in such a short time frame.
Evidence for this mechanism has come from experiments in vivo that examined 
ϐluid movement with changes in mean arterial pressure in small intestine that was 
rendered unable to absorb ϐluid [7]. This was achieved by using perfusates that 
were devoid of sodium ion and also contained ethyl-isopropyl amiloride. This was to 
prevent sodium ion absorption and hence ϐluid absorption from any exudate seeping 
to the luminal surface and bringing with it sodium ion for subsequent absorption. In 
these experiments ϐluid secretion occurred as arterial blood pressure fell, reached 
a maximum and then reverted to ϐluid absorption, exactly as predicted by changes 
in the Starling forces. Model A cannot accommodate any effect of arterial pressure 
since it does not incorporate physical forces into the model. In seems very likely that 
intestinal secretion is caused by smooth muscle events in the vasculature. If further 
Enterocytes
capillary
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such supportive evidence becomes available in the form of intracapillary pressure 
measurements during enterotoxin exposure and the enterocyte ϐluid secretion 
hypothesis is conclusively shown to be false, it is highly likely that pathophysiological 
changes in the lung in cystic ϐibrosis are also being caused by changes in bronchial or 
vascular smooth muscle tone.
The context and structure of the present review of the relevance of two 
models for intestinal secretion to cystic fi brosis heterozygote advantage
The context: Present views on compromised lung function in cystic ϐibrosis assume 
that bronchial epithelial cells in common with intestinal epithelium have the ability to 
secrete ϐluid. Further that this secretion optimises the ϐluidity of lung mucus. The failure 
to secrete ϐluid to hydrate lung mucus is a large factor in the poor lung function in cystic 
ϐibrosis. This disadvantage is counterbalanced by the fact that the failure to secrete 
has a positive outcome when the cystic ϐibrotic gut is challenged by cholera or other 
secretion causing toxins. This heterozygote advantage explanation has increasingly to 
confront the view that intestinal secretion mediated by chloride transport through the 
CFTR channel is not how secretory diarrhoeal disease arises. Fluid secretion does occur 
in some forms of secretory diarrhoeal disease but it is just as likely to be mediated by 
the Starling forces across intestinal capillaries and not by the enterocytes. This has 
consequences for symptom relief and restoration of function in cystic ϐibrosis suffers. 
If the underlying cause of the malady has been incorrectly identiϐied, then attempts to 
remedy it by reference to the present intestinal secretory paradigm must fail or at least 
succeed only by chance. It is instructive to realise that although the enterocyte chloride 
secretion model has been dominant for over forty years, no speciϐic intestinal channel 
blocker has been invented and is in use today to interrupt secretory diarrhoeal disease. 
There has been the development of enkephalinase inhibitors but arguably owing their 
emergence to a historical knowledge of opiate pharmacology. CFTR restoring agents 
show promise but it is not clear that their site of action is the enterocyte. 
The relevance: The focus on an epithelial secretion model incorporated from 
the ϐield of intestinal secretion may deϐlect attention from other areas of merit for 
correction of CF pathology such as smooth muscle physiology. An approach based 
on correction of faulty bronchial epithelial cell CFTR channels is to repair them by 
pharmacological intervention or by genetic engineering. However, interruption of 
channel activity is desirable in diarrhoeal disease but not necessarily so in CF if a poorly 
functioning channel confers heterozygote advantage. Correction of this mutation is 
the basis for much of current research into CF since repair of the CFTR channel by 
gene transfer therapy should again allow secretion and make mucus less viscous and 
difϐicult to shift, if the intestinal parallel is valid. Identiϐication of how ϐluid secretion 
is achieved in the intestine and whether the enterocyte is the correct target tissue 
for anti-diarrhoeal compounds is all the more pressing since clinical trials and key 
experiments to rectify CF defects by genetic engineering appear to be disappointing. 
In recent clinical trials, [2] involving inhalation of a gene transfer vehicle, it is arguable 
that lung function improved not at all or only trivially as assessed by forced expiratory 
volume measurements in cystic ϐibrotics. While the claim was made that gene therapy 
had ‘stabilised’ the CF patients, an alternative and pessimistic but valid interpretation 
is that the ‘placebo’ treatment of usual therapeutic measures itself caused some 
deterioration in lung function and the gene therapy did nothing.
For this reason, the evidence for a selective advantage to CF heterozygotes has been 
examined together with a review of the work done to date on intestinal manifestations 
of CF disease. In particular, the likelihood that the selective advantage is one of muted 
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secretion in cystic ϐibrosis through the enterocyte CFTR channels is reviewed and found 
to be unlikely. An alternative explanation for the ϐindings in CF is proposed-namely 
that hitherto unremarked but increasingly emphasised changes in vascular and small 
intestine smooth muscle may make CF tissue incapable of vasodilatation and hence also 
unable to secrete ϐluid. This review interprets data from CF studies in the light of poor 
vasodilatory and perhaps generalised poor smooth muscle function. Vasodilatation is 
a credible mechanism for diarrhoeal ϐluid secretion in normal individuals challenged 
by enterotoxins and lack of vasodilatation is a good explanation for lack of secretion 
in CF patients. The fact that there may be a relative lack of vasodilatation in CF and a 
generalised smooth muscle pathology based on CFTR mutations indicates that there 
are very many other possibilities for the heterozygote advantage, none of which need 
involve the intestinal epithelium. Dysfunction in cystic ϐibrosis sufferers is reviewed 
necessarily in the context of evidence for the ϐluid secretion model in cystic ϐibrotic 
intestine and refractoriness to some forms of diarrhoeal disease. This makes many 
demands on the reader who is familiar with respiratory physiology but not necessarily 
with intestinal physiology and pathophysiology. In addition, evidence for the existing 
and also for the intended replacement secretion model is drawn from several sources 
as diverse as population genetics and the mathematics of ϐluid ϐlow in tubes. For that 
reason, the essential points of each section are given here in prećis form, so that the 
basic theme can ϐirstly be appreciated and then the speciϐic detail and review of the 
evidence considered in greater detail in the indicated sections.
Prećis of salient points in the following sections of this review
• Cystic ϐibrosis pathology is thought to be related mainly to the defective cystic 
ϐibrotic transmembrane regulator (CFTR) channel.
• The assumed function of this channel is chloride ion and water secretion from 
lung tissue, resulting in failure to hydrate mucus when channel function is 
impaired by a deleterious mutation.
• Repair of this channel in lung epithelium is regarded as a desirable therapeutic 
aim.
• A difϐiculty with this approach is the reliance on the correctness of the 
enterocyte chloride secretion model to explain diarrhoeal secretory disease and 
its incorporation into the CF model of poor lung function.
• Gene transfer therapies have to date produced only very minor, possibly even 
negligible improvements in lung function. 
• If enterocyte chloride ion secretion does not occur, it is also likely that it does 
not occur in epithelial tissue in the respiratory system and cannot be modiϐied 
to effect ϐluid secretion.
• The persistence of the cystic ϐibrosis gene in the population is proposed to be 
the conferral of heterozygote selective advantage. This view is largely based on 
family size considerations and a conjecture that secretory diarrhoeal diseases, 
particularly cholera, may not occur as frequently in CF heterozygotes.
• The human evidence for heterozygote advantage is based on family size which 
is an act of human choice and not selection pressure. There is also no evidence 
for a selective advantage stemming from refractoriness to cholera.
• Early work on CF tissue points to a chloride ion transport abnormality but 
work on human heterozygotes points to a chloride absorption defect and not a 
secretion defect.
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• Mucus is tenacious in the intestine, evidenced by difϐicult to reconcile unstirred 
layer measurements with slightly better glucose absorption measurements.
• Overlooked older histology indicates swollen villi in CF sufferers indicative of 
unrestrained absorption in the intestine not a failure to secrete ϐluid. In animal 
studies, thicker smooth muscle is found in cftr knockouts.
• Mathematical modelling of lung function shows increased damping and stiffness 
in cf mouse knockouts, i.e. physical factors associated with airways alteration.
• Past observations indicate a failure in cystic ϐibrotic subjects to vasodilate, 
also a smooth muscle property. The most recent generation of CFTR channel 
inhibitors may also act on smooth muscle.
• A view that harmonises lung and intestinal pathology in cystic ϐibrosis is 
that both intestinal and vascular smooth muscle is thicker in CF, making the 
vasculature resistant to vaso-dilatation.
• The selective advantage in this case could be partial or multifactorial and relate 
to a failure to vasodilate. This would give some advantage in those diarrhoeal 
diseases that involve bacteria producing vasoactive agents that cause the tissues 
to vasodilate e.g. cholera toxin and VIP production.
• Other forms of selective advantage are conceivable based on refractoriness to 
vasodilatation e.g. cerebral vascular events.
• CF lung pathology may be more likely to respond to restoration of lung 
vasculature or bronchial smooth muscle ability to alter muscle tone.
• A more recent approach to CF therapy involves chloride channel activators but 
these also seem to involve alterations to bronchial smooth muscle and vascular 
smooth muscle
Review of the evidence for the epithelial focus of cystic fi brosis and the 
associated selective advantage hypothesis
Preface: The purpose of this main body of the review is to critique the evidence 
for the incorporation of the enterocyte secretion model into views on cystic ϐibrotic 
pathology. The persistence of the cf gene in the population is thought to arise through 
heterozygote advantage. If the adopted epithelial cell chloride secretion model is found 
to be false, then it is also evident that the reasons for heterozygote advantage cannot 
be referred back to the mutated cftr channel in the epithelium of lung tissue. The case 
is made for smooth muscle dysfunction being the essence of cystic ϐibrotic disease.
Introduction: Cystic ϐibrosis is an autosomal recessive disease that is carried by 
between 1 to 2 % of the Caucasian population and is therefore a common genetic 
disorder. The features of the disease include secretion of viscous mucus and, with that, 
a propensity to lung disease because respiratory mucus is difϐicult to shift from the 
lungs. Pancreatic enzyme and electrolyte secretion is affected which leads to upper 
gastrointestinal tract acidity as gastric acid is no longer neutralized, together with 
a need for pancreatic enzyme supplementation. There are also abnormal aspects to 
sweat gland secretions since cystic ϐibrotic sweat contains more chloride ion than 
usual. This ability to secrete sweat with a high chloride ion concentration forms the 
basis of a test for the occurrence of cystic ϐibrosis. 
Defective chloride channel (CFTR) in cystic fi brosis
Heterozygote advantage concept: Selective advantage requires that there must be 
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some form of selection pressure that favours the survival of certain genes. Otherwise, 
unfavourable genes put the carriers of such genes at such disadvantage that either 
they or their offspring have lesser survival rates than the normal population. This is 
particularly evident when a lethal gene is autosomal and dominant. A familiar example 
is the sickling gene which allows red cells to collapse onto malarial parasites in the 
blood of the heterozygote form giving heterozygote advantage in a malarial area.
The genetic defect: In the late 1980s, a genetic defect associated with cystic ϐibrosis 
was identiϐied as coming from chromosome 7, the gene product of which was a 
defective chloride channel protein [8,9]. The channel is named CFTR (cystic ϐibrosis 
transmembrane regulator) because it regulates other ion transport channels. CFTR 
is a ubiquitous chloride channel protein that is found in many tissues but research 
at ϐirst focussed on the intestinal effects of CFTR since its discovery. In part, this is 
probably because of the dominating presence of the enterocyte secretion hypothesis 
in the ϐield of intestinal secretion and the perceived likelihood of a similar role in lung 
epithelium to explain CF pathology. Two things are evident in the above example. With 
a lethal gene, the percentage of carriers in the population must inevitably be small, so 
small that any decline in allele frequency is difϐicult to detect unless there is massive 
screening of entire populations on a repeated basis, with allowance made for new 
entrants into the gene pool from outside the catchment area. It is therefore difϐicult to 
verify a decline in frequency of a rare lethal gene. The second point is that there has 
presumably to be an identiϐiable selection pressure for there to be selective advantage 
for the heterozygotes. When a population moves away from the selection factor e.g. 
when Africans are transported to America out of the malaria infested regions, the 
heterozygote advantage should disappear.
Likelihood of a selective advantage to heterozygote carriers of the CF gene 
Evidence for selective advantage: As a recessively inherited trait, the cystic 
ϐibrotic gene should exit from the gene pool if the carriers of the trait fail to reproduce 
or die before reaching the age of reproduction. Given the present day incidence of the 
cystic ϐibrotic gene, it is possible to estimate from Hardy-Weinberg calculations that 
a mutation giving the defective gene may have arisen relatively recently in human 
history. This could arise as a spontaneous mutation, as recently as twenty ϐive or so 
generations back, as late as 1100 AD, perhaps later given the life expectancy of the 
Middle Ages. On the other hand, it is also possible that the defective gene remains in 
the gene pool at a given frequency because the asymptomatic carriers of one defective 
allele have a survival advantage. The apparently higher than expected frequency of the 
CF gene in people of European or Caucasian origin has led to the search for the root 
cause of that selection pressure. In particular, there have been attempts to demonstrate 
the fact of selective advantage by showing the existence of increased frequency of 
descendants in people with cystic ϐibrotic lineage. The argument runs that there will be 
more people in such families having a cystic ϐibrosis sufferer in a previous generation 
when compared to the normal population. The grandchildren of grandparents who 
had a cystic ϐibrotic child should be more numerous than those of grandparents who 
did not, since the offspring should or at least might show some propensity to survive 
adult or childhood diseases or hazards.
The proposed evidence for selective advantage of the heterozygotes therefore 
mainly resides in two very similar studies of families with a cystic ϐibrotic child and 
those without, in an attempt to assess the outcomes for the descendants. In one 
study [10], families with a CF child were asked to participate and also to name for 
participation purposes, two comparable families from their friendship group, without 
a CF child. This device was intended to standardise for age, social grouping and living 
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conditions on the basis that these families would not be too dissimilar or not be 
subjected to very different environments. When this was done, it became evident that 
one striking difference was that cystic ϐibrosis families had larger family sizes. This 
was statistically signiϐicant and indicated a mean difference of about 0.6 people per 
family. This conclusion from this Australian study was conϐirmed by a contemporary 
one in the US which ranked the families by family size. Unlike the Australian study 
[10], which provided an overall mean difference, the US study [11] compared by family 
size so that the size distribution was also known. The family size was looked for in the 
grandparental generation since they were parents who had had a CF child and were 
both heterozygotes for the cystic ϐibrotic gene. It was clear that, on average, combining 
all families over the size range, there were more offspring in the grandparental 
generation of the CF families group, the difference being about 0.91 children per family. 
On average, the size of the families was also larger. The normal modal value was two 
children per family but was three children in the antecedents of the CF families. 
In general, the greater number of offspring arose through larger family size. This 
can be tested by applying the standard χ2 test to the various family size contingencies. 
The range of families was large, extending to family sizes in the low teens but these 
were size contingencies with relatively low frequencies of occurrence of one or two 
families. In accordance with recommended practise, contingency size should be 
selected to have four or more occurrences in each contingency. When this is done, 
difference in distribution by the χ2 test was shown to be highly signiϐicant, (p<0.01) 
meaning that the family size was larger in the CF antecedent generation. The greater 
preponderance of siblings in the preceding generation has been assumed to be proof 
of selective advantage. The appropriate calculations can then be done to estimate 
the extent of advantage in the face of selection pressure, as was indeed done [11] in 
accordance with the principles of quantitative genetics. However, this may indicate the 
extent of advantage only if it is accepted that the fact of excess births is an aspect of 
evolutionary advantage. Are there no other explanations?
With most forms of selective advantage, one might anticipate the unknowing and 
unself-conscious hand of evolution directing survival in the form of an advantage at 
the cellular level, such as a biochemical mechanism or the collapse of red blood cells 
onto a parasite, where there can also be no question of the involvement of conscious 
thought. In contrast, human family size is an act of human volition, involving the choice 
to have children. It is therefore not at all self-evident that the larger families’ sizes are 
a genuine manifestation of selective advantage.
Ancestral residence in a diarrhoeal disease endemic area: In the case of cystic 
ϐibrosis, after the discovery of the defective CFTR channel and its incorporation into the 
theoretical mechanism for ϐluid secretion, it was proposed that there was a selective 
advantage to not secreting ϐluid. If the population under consideration resided in 
an area where life threatening diarrhoeal diseases were present, the carriers of the 
dysfunctional CFTR channel would enjoy a selective advantage. The people in question 
would be those of European or at least Caucasian ancestry since they have the highest 
allele frequency and their ancestors should have lived in a diarrhoeal disease endemic 
area. The defective CFTR channel was initially proposed to be a response to cholera 
[12] and would require that the Caucasian ancestors lived near the source of cholera. 
Epidemics of cholera such as those that spread throughout Europe in previous centuries 
are generally agreed to have started close to the Bay of Bengal [13] where the disease 
is endemic, though not all would agree with the premise that cholera is solely of Asiatic 
origin [14]. In order to acquire a selective advantage, the Caucasian population should 
have resided for many generations near the Bay of Bengal. This question of prolonged 
residency is a problematical question for population geneticists and also for linguists 
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interested in the spread of language. Accompanying the recognition that the Indo-Aryan 
languages have spread throughout the world is the associated but vexed problem of the 
geographical origin of the Indo-Aryan language speakers. Some authorities [15] place 
their origin in Anatolia in eastern Turkey, other authorities [16] provide evidence for 
their origin being in the Pontic-Caspian region near southern Russia. There is also the 
associated problem of what Caucasian means because it is essentially a euphemistic 
term for white people, assumed to be a sub-set of the Indo-Aryan population. There 
is also the caveat that the spread of language does not necessarily correspond to the 
spread of a migrating people. 
 On balance, it is likely that most Indo-Aryans did not reside near the Bay of Bengal 
for a long period of time. A subset of Indo-Aryans migrated south but was unlikely to 
have entered the region until 3000 BC or later. It seems that the fractional split in the 
Indo-Aryans and their late entry of some of them into the cholera endemic area makes 
it unlikely that cholera was the relevant selection pressure. At a later date, the view 
arose [17] that cholera was unlikely to have been the selection pressure. Exposure to E. 
coli enterotoxins was substituted as the likely factor as humans have been interacting 
with E. coli for longer. The problem with this modiϐied hypothesis is that there is no 
obvious group or population that is particularly affected or even unaffected by E. coli 
enterotoxins. The selection pressure would be present everywhere with no obvious 
epicentre or reason for any particular population slowly to derive a selective advantage.
Studies on Indo-Aryan migration makes cholera an unlikely selection 
pressure
Possible selection pressures: There is the additional objection that the heat stable 
form of E. coli enterotoxin is not secretory and does not require a chloride channel to 
effect lack of ϐluid absorption, [18], although at present, few researchers in the ϐield 
would agree with that view. If this is accepted, then the argument for the intestinal 
aspect of selection pressure becomes even weaker since only E. coli enterotoxins 
such as LT would be secretory. Enterotoxins that remove cells or alter tight junction 
permeability would also not constitute a pressure against which a defective chloride 
channel could provide an advantage. However, selective advantage can still be 
proposed if one discards the idea of CFTR being involved in secretion into the intestine 
(i.e. abandonment of the enterocyte secretion hypothesis) and one proposes instead 
a survival advantage to cystic ϐibrotics heterozygotes because of improved lung or 
smooth muscle function.
Improved lung function or altered smooth muscle physiology may be the 
selection pressure
Diagnosis of cystic ϐibrosis: Earlier work on cystic ϐibrosis investigated the 
feasibility of diagnosis without intrusive clinical function tests. This concentrated on 
measurement of skin chloride ion concentrations in the sweat and also testing blood 
samples. It had long been the received wisdom of midwives that cystic ϐibrosis could 
be detected by licking a new born baby’s forehead and checking for excessive saltiness. 
From this observation developed the diagnostic procedure of screening sweat in 
paediatric patients for excessive chloride ion concentrations. Normal sweat contains 
16 mM chloride ion and 23 mM sodium ion while cystic ϐibrotic sweat contains 99 
mM chloride ion and 101 mM sodium ion [19]. This itself seems to be an anomalous 
occurrence given that dysfunctional CFTR should be associated with failed chloride 
secretion in cystic ϐibrotic children. This was perhaps the ϐirst indication that the 
problem with possessing dysfunctional CFTR is not the failure to secrete but the failure 
to absorb through the broken channel. This alternative view would be consistent with 
physical secretion of isotonic ϐluid, with subsequent retrieval of cations and anions by 
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absorption mechanisms, as occurs in the renal tubules. It is likely that sweat is initially 
an exudate of plasma secreted because of hydrostatic pressure gradients across the 
gland membranes with re-absorption of electrolyte content within the sweat ducts or 
secretory coil in order to provide a hypotonic secretion for evaporation at the skin 
surface. This model of isotonic exudation followed by selective retrieval of sodium and 
chloride ions would resemble that occurring during salivary secretion where again at 
low salivary ϐlow rates, the secreted ϐluid is hypotonic, perhaps reϐlecting again the 
physiological imperative for a land dwelling mammal not to lose salt. High chloride 
concentration in the sweat might then reϐlect a failure to re-absorb chloride ion 
resulting in a high concentration in the secreted sweat.
An intestinal factor: Attempts to diagnose cystic ϐibrosis have included taking 
blood from a patient, spinning the red cells down and measuring the fall in short circuit 
current in intestinal tissue in vitro exposed to the serum. Cystic ϐibrotic serum reduced 
short-circuit current in rat jejunum [20] an effect that could be overcome by heating 
the serum. The action on short-circuit current was conϐirmed [21] for heterozygote 
and homozygote serum, although in a larger study, both heterozygote and normal 
blood serum reduced the short circuit current by 40% but the homozygote serum 
gave higher values with the median value clustered at closer to 65% inhibition [22]. 
This heat labile factor did not seem to be important when considering the possibility 
of inhibiting glucose uptake as assessed in vesicles [23], perhaps indicating that CF 
serum will act only on ion channels.
Experiments on in vitro intestinal function in cystic fi brotic tissue
In vitro experiments: Intestinal tissue taken during surgical operations to relieve 
intestinal obstructions can be investigated for intestinal function using the venerated 
in vitro techniques of short circuit current and isotope ϐlux measurements, neither of 
which technique is ϐit for the purpose of detecting secretion [3,4]. In an Ussing chamber, 
small intestine from non-CF tissue demonstrated increased short circuit current after 
theophylline, prostaglandin E
2
, A23187 and bethanechol exposure while CF tissue did 
not. Similarly, in colonic tissue, theophylline and A23187 were able to elevate short-
circuit current in non-CF but not in CF tissue. Reprising the situation with serum factor 
experiments, both CF and non-CF tissues demonstrated an increase in short-circuit 
current on perfusion with glucose, indicating that sodium ion-dependent glucose 
uptake was not inhibited [24]. Preliminary studies in a small group of biopsies showed 
that CF jejunum did not respond electrically to luminal acetylcholine or to PGE
2
 whilst 
retaining a muted response to glucose perfusion [25]. Similar short-circuit current 
studies showed an absence of a voltage response across the jejunum in CF patients 
when pilocarpine and PGE
2 
were given. Normal tissue experienced a rise in short-
circuit current after dibutyryl AMP and A23187 exposure but the response in CF tissue 
was absent or very small [26]. Curiously, despite recording large intraluminal pressure 
waves in cystic ϐibrotic and normal jejuna, only the normal jejunum responded with 
changes in transmural voltage, implying the inability to mount a secretory response 
because of a lack of functioning chloride channel. The likelihood of CF tissue not 
receiving afferent information about pressure events or something unusual concerning 
CF smooth muscle [27] was not considered at the time.
Isotope ϐluxes in CF tissue failed to demonstrate the changes that were characteristic 
of non-CF tissue, particularly the increase in luminally directed isotopic chloride ϐlux 
after theophylline exposure. Similar refractoriness of short-circuit current in CF tissue 
after 3-iso-butyl-methylxanthine (IBMX) exposure was conϐirmed, as well as the lack 
of enhancement in the luminally directed chloride (Jsm) ϐlux in CF tissue [28]. In the 
former study, it is noteworthy that the chosen ‘secretagogues’ are all capable of causing 
vascular smooth muscle relaxation, which is relevant to the alternative explanation of 
the origin of the short circuit current expressed here.
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Experiments on secretory function using CFTR knock-out mice
Knock out experiments: With the discovery of the defective CFTR gene product 
stemming from chromosome 7, this area has been targeted to provide heterozygous 
and homozygous knock-out mice for CFTR for comparison of secretory function with 
that of wild type mice. In humans, the defect concerning CFTR is its lack of functioning, 
mainly by a failure to be inserted into the luminal membrane but also by partial lack 
of function because of permeability defects, despite correct insertion into membranes. 
Mice that have had CFTR production capacity deleted from their DNA are models 
therefore of cystic ϐibrosis sufferers but are not exactly analogous, given the fact the 
human cystic ϐibrosis is characterised by mutations of the gene rather than absence. 
Given the ability to knock out genes in mice, investigations were initiated on the effect 
of an absent CFTR channel on the ability to secrete ϐluid, since, in accordance with 
the enterocyte secretion model, cftr (-/-) mice should not be able to secrete ϐluid in 
response to putatively known stimuli of intestinal secretion.
Short-circuit current studies: Using the ΔF508 mutant colon from heterozygous 
mouse, the short-circuit current responses (a proxy for secretion) were no different 
in CF and in normal mouse tissue to stimulation by VIP and by forskolin [29] neither 
were the short-circuit current responses to cholera toxin. Short circuit increases 
were identical after isoprenaline, E. coli STa enterotoxin, guanylin, lysyl-bradykinin 
and carbachol. Frusemide action was also not different in the two types of tissue. As 
previously, increase in short-circuit current was assumed to be chloride secretion 
and this is clearly not the case with STa exposure since no net secretion is ever found 
with this enterotoxin [18]. Again, these observations may be of greater relevance to 
what causes the rise in short circuit current. All these compounds either cause smooth 
muscle vasodilatation (VIP, forskolin, isoprenaline, bradykinin and carbachol) or 
inhibit sodium ion: hydrogen ion exchange and subsequent luminal acidiϐication (STa, 
carbachol, guanylin), hence the increase in short-circuit current is again consistent 
with the vasodilatation reϐlex that has been proposed [30]. If one accepts, without 
reservation, the chloride ion secretion hypothesis, no advantage seemed to be 
conferred by the ΔF508 CF mutation.
An interesting aspect of short-circuit current ϐindings in CF mice [28] is the likelihood 
that some if not all of the current is an inwardly directed electrogenic sodium ion 
current and not outwardly directed chloride ion current. This only becomes apparent 
when the electroneutral sodium ion absorption mechanism is compromised. Amiloride 
does little to short-circuit current in mouse colon prior to guanylin stimulation but it 
moderately inhibits the rise in short-circuit current after guanylin is administered. In 
the absence of chloride ion, the effect of guanylin is attenuated. In CF mouse colon also, 
amiloride also reduced the increment in current detectable after guanylin addition. 
In CF tissue as well as normal tissue, part of the short-circuit current increase occurs 
because guanylin has acted on the NHE: 3 system and ‘can cause electrogenic sodium 
absorption’ [31].
In other words, when the NHE: 3 exchanger is functioning, guanylin inhibits it and 
associated ϐluid absorption, with amiloride having no effect. When this electrically 
silent mechanism for ϐluid absorption is inhibited by guanylin, short circuit current 
increases because an electrogenic mechanism comes into existence; this is now 
inhibitable by amiloride whereas it wasn’t before.
Short-circuit current studies in knock-out mice conϐirm the ‘refractoriness’ in 
CF intestine to secretion, when this is equated to change in short-circuit current. 
Undoubtedly, short-circuit current does change but this is likely to be stimulation of an 
electrogenic sodium ion uptake current and not chloride ion secretion.
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In vivo ligated loop studies: When ϐluid movement was measured in another 
mouse model by a ϐluid accumulation ratio method, cholera toxin caused a large luminal 
ϐluid to gut mass ratio in normal mice. There was a low ratio in homozygous mice and 
an intermediate value for heterozygote mice. It should be noted that short-circuit 
current was increased in the CFTR(+/-) mice but not as much as the CFTR (+/+) did 
[32]. Similarly, the actual values of ϐluid retained and gut weight are not given. While 
these observations are often taken as evidence for enterocyte chloride ion secretion, 
intercellular extrusion of ϐluid from the vasculature into the lumen also explains these 
ϐindings. In this case, there would be a heterozygote advantage in not being able to 
extrude ϐluid into the lumen, with the cause of this residing within vascular smooth 
muscle.
In vivo studies show reduced secretion after exposure to cholera toxin in cf mice. 
This is consistent with reduced secretion through the chloride ion channel but an 
argument with greater validity is the refractoriness of CF smooth muscle to relaxation.
Aspects of histology: A curious aspect of the histology of cftrtm1Unc mouse [33]; 
(Figure 1) is that while there are mucus deposits in dilated crypts, an unremarked 
feature is the width of the villi in the cftr deleted mouse which is considerably wider 
(156 um v 100 um in normal mice) at the mid-villous point and the lesser intra-villous 
space (10um v 30 um in normal mice), with the width at the villous at the tips being 
almost doubled. Similar widening of the villus is just discernible in the cftr mutants 
in gene delivery studies [34]. This is consistent with intestinal tissue having a large 
interstitial ϐluid volume due to increased rates of intestinal ϐluid absorption, decreased 
exit of ϐluid into the vasculature or a combination of both. It may be that tenacious 
mucus that blocks the crypt lumina prevents the translocation of guanylin to the 
villous tips to lower ϐluid absorption by inhibiting the NHE: 3 exchanger. Hence, the 
intestinal obstruction problems in cftr defective mice may be caused by uninhibited 
ϐluid and therefore excessive absorption rather than the usual conjectured failure of 
ϐluid secretion. A non-functioning cftr channel may be a way of reducing excessive 
absorption to make mucus less viscous.
Later in vivo perfusion experiments on cystic fi brotic patients
Human studies: More recent studies have involved intestinal perfusion of the 
jejunum of cystic ϐibrotic patients with low chloride ion containing perfusate in order 
to maximize the potential for getting information about chloride ion movement. The 
lumen was found to be slightly positive in CF and non CF patients but became negative 
on perfusion with theophylline in the non-CF patients but was unaffected in CF patients. 
According to the authors [35], increased lumen negativity (increased serosal surface 
positivity) can only be explained by increased anion secretion or decreased (sic) cation 
absorption. In non-CF control patients, theophylline increased water secretion but did 
not do so in the CF patient group. Luminal chloride ion concentrations were also higher 
in the control group and rose on theophylline stimulation but were low in the CF 
patients and remained so despite theophylline administration. This is again consistent 
with the enterocyte section hypothesis but does not add substantial proof because the 
ϐlows of ϐluid and the lack in CF might also arise from changes in vascular tone.
Testing the heterozygote advantage hypothesis: It was evident from perfusion 
studies that abnormal passive chloride absorption in cystic ϐibrosis jejunum did 
not agree with the classic view of a chloride secretory defect [36]. The question of 
heterozygote selective advantage was therefore addressed directly by intestinal 
perfusion in cystic ϐibrotic ΔF508 heterozygotes perfused principally with an isotonic 
sodium chloride and sodium sulphate solution. The heterozygote CF group secreted as 
much ϐluid as the normal group, also when secretion was stimulated by prostaglandin 
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1
. Homozygous CF patients did not secrete ϐluid signiϐicantly after PGE
1
 perfusion. 
In this case [37], human heterozygotes do not show the heterozygote advantage that 
they are supposed to have and which seems to be evident in the mouse knock-out 
model. When normal balanced electrolyte solutions were perfused, containing glucose, 
glucose was absorbed at the same rate in normal and heterozygote CF subjects but 
there was no sodium or chloride ion absorption in cystic ϐibrotic patients and 
increased ϐluid absorption was only one third of control values. This, together with 
differences in mannitol induced potential differences, indicated that the known lack of 
chloride ion permeability acts to prevent normal ϐluid absorption and is not associated 
with increased ϐluid secretion. The malfunctioning chloride channel in CF seems 
therefore to be a poorly functioning chloride channel that does not allow complete 
chloride absorption. In conclusion, there is not only a lack of evidence for heterozygote 
advantage in CF , there is also now evidence against it and an alternative view that CF 
mutations lead to a damaged chloride uptake rather than a secretory process.
Earlier work on rectal potential difference in cystic ϐibrotic patients [38] conϐirms 
this view. Rectal transmural voltage difference was about -41 mV lumen negative in 
normal tissues and -21 mV in cystic ϐibrotic patients. This value fell by about 30 mV 
in the normal subjects and by a similar amount in CF, on perfusion with low chloride 
ion containing perfusate, enough to change the polarity of the CF transmural voltage. 
With STa, the enterotoxin that has no discernible secretory action [4] if ϐluid transport 
is appropriately measured by volume recovery, transmural potential difference 
increased in normal subjects but not at all in CF patients. This is consistent with STa 
inhibiting electroneutral NHE:3 exchange and inducing an underlying electrogenic 
method of absorption of sodium ion - with this not possible in CF because of the 
broken CFTR channel that prevents chloride ion uptake in association with sodium ion 
uptake. This event takes place after the interruption of normal sodium ion uptake by 
STa since both CF and normal tissue display increases in tissue cGMP content after STa 
exposure. The fact that enhanced chloride ion uptake takes place after STa challenge is 
clearly seen in non-cystic ϐibrotic cultured colonocytes. On exposure to STa, chloride 
uptake into these cells increases threefold and can be inhibited by furosemide and 
DPC, the chloride channel blocker. If these compounds blocked NKCC1, only reduced 
chloride ion uptake might be expected. If STa caused chloride ion secretion, uptake 
of chloride ion might reasonably be expected to be reduced but was not. These 
observations are entirely consistent with those of Fordtran’s group who convincingly 
demonstrated a failing chloride uptake mechanism, not an enhanced chloride ion 
secretory mechanism in cystic ϐibrotic heterozygote patients. While increased chloride 
ion uptake was detected in the colonocytes, the authors themselves [38] concluded 
that human colonocytes secrete chloride ion (summary paragraph) in response to STa, 
emphasising the increase but neglecting the direction of that movement i.e. into not out 
of the colonocytes as required by secretion.
Findings in CF patients in support of the tenacious mucus concept
Evidence of viscous mucus: Most CF research has focused on the CFTR channel 
and its likely role in the prevention of chloride ion secretion as proposed by the 
doctrine of chloride ion secretion emanating from enterocytes and also the likely 
selective advantage that disruption of the secretory channel might confer. Sometimes, 
research work is reported that emphasizes the fact that secreted mucus alters 
histological appearance or the physiological outcomes of absorption experiments. 
CF mice require a 6% polyethylene glycol supplemented electrolyte solution i.e. 
hypertonic saline, in order to ensure greater survival rates and prevent death from 
intestinal obstruction from which particular genotypes suffer [33,39]. Where intestinal 
perfusion experiments are done in CF patients, a minor but noteworthy aspect of the 
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process is that perfusion catheters become clogged in all CF patients, though only in 
1 of 9 control subjects, highlighting the very viscous mucus in the CF patients [35]. In 
histological slides made of CF biopsies, the lumina of the crypts are dilated with PAS 
positive mucus like material [40]. In this paper, oedema within the villi is stated (text to 
Figure 1) but without further comment in the discussion. Oedema might be unusual in 
a tissue that was incapable of secreting but would not be discordant in a tissue where 
absorption from the lumen was unregulated. This might arise if ϐluid absorption was 
no longer a controllable event through local movement of guanylin from the crypts 
to the villous tip cell. Sticky mucus might prevent the diffusion of this local paracrine 
agent to the target cells. Similar concentrations of mucus were also found in the ileal 
and colonic crypt lumina of cftr knockout mice [34].
Unstirred layer thickness and glucose uptake: Viscous mucus within the crypts 
might explain the occasional observation of slightly enhanced substrate absorption. 
Enhanced glucose and alanine transport was claimed for CF intestine [41] on the basis 
of electrical measurement but conϐirmed by direct measurements in perfused intestine 
[42]. Here, the Km for glucose absorption was found to be lower in CF than in normal 
intestine and the unstirred layer thickness was found to be considerably smaller in 
CF. Curiously, the authors argue that abnormal mucus over the tips of the villi causes 
thinning of unstirred layer thickness. 
 Unstirred layer thickness is deemed to be the thickness of an aqueous layer above 
the villi bounded by the villi on one side and a notional stirred: unstirred boundary at 
the other end. Substances have ϐirst to diffuse across this layer in order to reach the 
absorbing epithelial cells. Typical values for the length may represent this aqueous 
layer thickness and to a lesser extent the gap between the villi extending down 
towards the crypts. Unstirred layer thickness is determined by an electrical method of 
solution change where altered bulk phase sodium ion concentration causes diffusion 
into or out of the unstirred layer and then beyond and probably down the length of 
the villi. There is no reason to assume that solute diffusion stops when the advancing 
solute front has reached the tips of the villi and that there is no onward diffusion down 
into the intravillus space. Hence, unstirred layer length measurements are probably 
composites of villus length and unstirred layer above the tips. 
If the cystic ϐibrotic mucus, known to be present in the crypts, is a tenacious barrier 
to diffusion, then diffusion down the intervillus space is probably prevented to a certain 
extent, thereby shortening the apparent unstirred layer length. It is notable that the 
difference in unstirred layer length was estimated to be 780 for normal subjects minus 
- 546 or 234 um, close to the length of a villus which would be unusual. Cystic ϐibrotic 
villi would have to be visibly shorter than normal villi if this were true. In addition, 
higher substrate concentrations obtain at the absorbing villus tip sites and would not 
be lower than normal in CF because of diffusion past and away from the tips down the 
intervillus space. Substrate would therefore cross the aqueous region to reach the villi 
but in the case of CF tissue with inspissated mucus, the solute front would pass only 
very slowly down the intervillous space, making it seem like the diffusion path was 
shorter. It is highly likely that these observations result from the tenacious mucus that 
is associated with CF and result from an increase, not from any decrease in diffusion 
barriers. 
Consequences of tenacious mucus
The viscous mucus associated with cystic ϐibrosis may be the cause of the various 
problems associated with CF since difϐicult to dislodge mucus impacts on any ϐlow 
down ducts and indeed movement in the trachea. It may be that the mutational defect 
in cystic ϐibrosis has survival value precisely because the ion channel is defective in 
CF or not inserted into the membrane. This would imply that CFTR is an important 
chloride channel that is required for uptake of ϐluid and not secretion. Where ϐluid 
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uptake continued uninterrupted, it would lead to the production of viscous mucus 
that would make lung and pancreatic function abnormal because of blockage of ducts 
and difϐiculty in shifting mucus in the lung. A mutation in the CFTR channel could 
presumably reduce the rate of ϐluid absorption and allow the mucus to be less viscous 
than would otherwise be the case. 
Relief through interrupted absorption: Some studies in cftr mutant mice support 
this concept. Where ϐluid uptake mechanisms are compromised, there is increased 
survival of CF mice; in cftr (-/-) knockout mice, with intact NHE3, survival time is poor 
with most not surviving beyond six weeks. Double knock-out cftr (-/-) and Nhe3 (-/-) 
mice have 75% survival rates at eight weeks, demonstrating clearly that inability to 
absorb ϐluid protects against cystic ϐibrotic pathology [43]. 
It is possible that the essential pathology of CF is pathological mucus formation in 
the lung and that mutation in CFTR prevents ϐluid absorption. The selective advantage 
to defective or otherwise inoperative CFTR could be that ϐluid absorption in the lung 
bronchioles is inhibited and mucus is kept more hydrated than it otherwise might be. 
This might explain why there are very many mutations in CFTR because the mutations 
confer survival. This implies that lung function is improved slightly but the alteration 
in CFTR causes coincidental changes in sweat and saliva secretion that are not as 
life threatening as the impaired lung function, were chloride absorption to be left 
unchecked.
Observations on the identifi cation of defective CFTR protein as the key 
aspect of cystic fi brosis
Review of the genetic research: At the present state in cystic ϐibrosis research, 
it is arguable that the concept of selective advantage of the heterozygote condition in 
the intestine through reduced chloride secretion has been tested and shown to be very 
unlikely. Associated phenomena related to defective CFTR and the intestine seem to 
be related more to short-circuit current measurements that could have their origin 
remote from the enterocyte cells. If that is so, then a reason must be found for why a 
consistent ϐinding in CF studies is the refractoriness to substances that stimulate short 
circuit current in normal tissues. Before providing a possible reason, there may be some 
merit in reviewing the background to the identiϐication of CFTR protein as the essence 
of the problem of cystic ϐibrosis, and with that, the identiϐication of chromosome 7 
as the source of the disorder. Identiϐication of the relevant chromosome was done by 
the process of detection of restriction fragment length polymorphisms which do not 
necessarily occur in genes. Some forms of RFLPs are inherited with particular diseases. 
This need not arise because the restriction site was created by the disease state but 
apparently only because the sequence is very close to the affected gene [44]. In addition, 
samples of cDNA were created from mRNA from affected cells such as sweat glands. 
The cDNA prepared from mRNA from an affected cell is the nucleotide sequence that 
encodes the relevant protein but not necessarily sequences that have been suppressed 
in that particular cell. It may be that the focus has been on a mutation in CFTR that 
allows survival beyond the uterus instead of the essential gene mutation that is the 
cause of CF and which might turn out to be a gene involved in mucus production.
Conclusion
There are aspects of CF phenotype that seem to be widespread in transporting cells 
wherever CFTR is present and there is no doubt that it is an important chloride channel, 
involved in sodium chloride transport. However, heterozygote advantage is unlikely to 
take the form of absence of secretion. Just as likely is a hypothesized protection against 
bronchial asthma [45]. There are undoubtedly aspects of the intestinal phenotype that 
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merit further investigation such as the apparent lack of diarrhoeal symptoms coupled 
with the presence of higher anti-body titres in cystic ϐibrotics in whom C. difϔicile 
bacteria are present in the intestine [46,47]. These isolated observations are pertinent 
to the hypothesis developed below of an inability of CF vascular smooth muscle to 
vasodilate to the same extent as normal vascular smooth muscle. It is well known 
that combinations of C. difϔicile toxins A & B cause genuine net ϐluid secretion into the 
intestinal lumen as well as exudate containing red blood cells, implying vasodilatation 
and increased capillary pressure forcing both plasma and formed elements of the 
blood into the lumen. A restricted ability for arteriolar vasodilatation would be an 
advantage when exposed to C. difϔicile and would explain the higher anti-body titres 
without obvious diarrhoeal symptoms. The current linkage of defective CFTR to poor 
secretion is unlikely given the lack of secretion in human heterozygotes. The link that 
does exist, (the notable exception of the very muted response to cholera toxin in CF 
mice), is only tenuously linked to enterocyte secretion through a rigid interpretation 
that changes in chloride ion movement alone are reϐlected in increased short-circuit 
current. What is proposed in the next section is an alternative explanation for the lack 
of secretion in CF patients based on pathological alterations in vascular smooth muscle 
that are consistent with the intestinal capillary ϐiltration model of ϐluid secretion.
Respiration abnormalities in cftr (-/-) mice
A major difϐiculty with cftr knock-out mouse models of cystic ϐibrosis has been the 
lack of evidence for a lung phenotype in the cftr (-/-) mouse. This may be because 
the anticipated phenotypic alterations were not what was eventually found. Static 
compliance of lungs assessed through lung pressure-volume relationships in cftr 
knock-out mice was found to be less than normal in the cftr (-/-) mouse but enhanced in 
the cftr (+/-) mouse [48]. Static lung compliance is a lumped parameter of all elements 
in the tissue that may reduce an increase in volume for a given increment in pressure. 
Dynamic properties were also measured by imposing a sinusoidal forcing function that 
altered lung volume. Impedance, elastance, inertance and viscance are the preferred 
terms used in lung physiology to indicate time varying resistance, elasticity, inertia 
and viscosity. The total impedance of the lung was measured and resolved into the 
separate components of airways resistance and airways inertance, combined with 
tissue damping (viscance) and stiffness (elastance) factors that also contribute to the 
total impedance.
Measurement of these latter properties relies on a mathematical treatment [49] of 
the pressure transients that occur on lung volume change. The unit impulse response 
treatment was extended to include forced sinusoidal variations in volume that precede 
by a given phase angle, the induced changes in pressure, so that pressure change will lag 
the imposed volume change. A later treatment, using Hildebrandt’s [49] derivation but 
using the integrated form of the Laplace transformation of time dependent equations 
[50] provides a compact solution that includes a term for viscance (G) and elastance 
(H). The Hildebrandt and the Hantos treatments of the factors involved in airways 
resistance are attempts to resolve individual contributions by making use of solutions 
to the fundamental problem of a volume based sinusoidal forcing function acting on a 
system that exhibits approximately simple harmonic motion that is damped. Hence, 
this allows for hysteresis effects and the loss of energy that should lead to decay of 
simple harmonic motion but for the repeated imposition of a volume change. 
Neglect of certain terms in Hildebrandt’s treatments of the inϐlation of the lung 
and the balloon gives, for the lung, what has come to be called the constant-phase 
model. Hildebrandt found empirically that the relationship of the pressure change 
per unit volume change was logarithmic in the lung but linear for the balloon. Using 
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the constant-phase model for the lung, Hantos and colleagues detected an almost 
twofold increase in damping in the dog lung and a third more increase in elastance 
after intravenous histamine infusion. There was also a doubling of airways resistance, 
as might be expected after contraction of bronchial smooth muscle. The increase in 
damping and stiffness is also presumably because the lung smooth muscle is in a more 
contracted state.
Using this model, Cohen and colleagues [48] showed that not only was the 
static compliance of the cftr (-/-) mouse lung reduced but also that the dynamically 
determined damping and stiffness coefϐicients were double the normal value and 
possibly also the airways resistance was increased. Heterozygote mice in contrast 
had slightly less dramatic reductions in dynamic airways resistance (impedance), 
damping and stiffness. It would be interesting to know whether the bronchial smooth 
muscle was thicker in cftr (-/-) mice and thinner than normal in the cftr (-/+) mice. 
The authors conjecture that this could be the heterozygote advantage that allows 
cystic ϐibrosis to persist in the population. However, given the lack of evidence for a 
demonstrable selective advantage based on population data, this question cannot be 
unequivocally answered. Nevertheless, even if this confers no selective advantage, 
the increased damping and stiffness reinforces the idea that a central aspect of cystic 
ϐibrosis pathology might be alteration in smooth muscle structure, somehow related 
to the defective chloride channel, perhaps related more to altered smooth muscle 
physiology than to inhibited enterocyte ϐluid secretion.
Evidence for changes in intestinal and vascular smooth muscle vasomotion 
in cystic fi brosis
A noteworthy but unremarked aspect of cftr (-/-) animals models of cystic ϐibrosis 
is the change in smooth muscle structure. In cftr mouse mutants, a threefold increase 
in circular muscle size was noted in the mouse jejunum [51]. Although no histology was 
presented, wall tension of mouse aorta rings was found to be three times higher in cftr 
(-/-) mice when compared with wild type control mice, together with very impaired 
muscular relaxation after VIP exposure [52]. Inhibition by CFTR (inh)-172 inhibitor 
of sphingosine-1-phosphate enhanced myogenic vasoconstriction occurs in hamster 
resistance arteries, again implying impaired vasodilatation [53]. Corroborative 
evidences comes also from human studies in which higher doses of the vasodilator 
isoprenaline were required in the hand veins of CF patients to achieve relaxation 
compared with normal subjects. In addition, the maximal venodilatation achieved 
was less in CF patients [54]. The apparent increase in smooth muscle thickness is 
also seen in VIP knock-out mice both in the lung and the intestine [55], together with 
interference with CFTR localisation.
The concept that failure of dilatation of smooth muscle occurs in cystic ϐibrosis 
sufferers or if not physiological difϐiculties in relaxation of smooth muscle, then 
thickening of the smooth muscle to prevent dilatation has been occasionally recorded 
in the literature on CF. A high percentage of portal hypertension occurs [56] in CF 
sufferers as well as carotid body hypertrophy [57], lung compliance is less in terms of 
change in volume per unit change in inϐlation pressure [48] in the lung of heterozygote 
and homozygote cftr (-/-) mice and intestinal circular muscle mass is greater [51], 
all pointing to physical or physiological reasons why smooth muscle does not relax 
normally in the CF state. 
Reduced relaxation of pulmonary arteries was found in CF patients [58] from tissue 
obtained at heart lung transplant. CFTR was determined to be involved in normal 
bronchodilatation with contraction inhibited by CFTRinh-172, the CFTR channel 
blocker, indicating the involvement of the CFTR channel in normal constriction of 
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the smooth muscle of the trachea. Innervation of the trachea was less in knock-out 
mice as was the muscle tone of the trachea [59]. Intestinal circular muscle is less co-
ordinated in cftr knockout mice and is also refractory to carbachol and curiously also 
to depolarisation caused by addition of KCl [60]. In addition, increased tissue levels of 
prostaglandins were found. In aortic rings from mice, the vascular tone is higher in cftr 
knockouts, again implying an inability to undergo smooth muscle relaxation and in this 
case, cftr (-/-) tissue responses to 80 mM KCl were also much higher than wild type 
responses [52]. Disrupting the CFTR gene reduces the response of vascular smooth 
muscle to vasoactive agents but also prevents some forms of vasodilatation.
The Cl– equilibrium potential is more positive than the resting membrane potential 
enabling Cl to be a depolarizing ion upon activation of a Cl – conductance channel but 
does not seem to ϐit in with the physiological role of CFTR in vascular smooth muscle 
[61]. The change in membrane potential towards depolarization is associated with 
contraction but does not accord with the ϐindings that CFTR is needed for contraction 
and CFTR inhibitors prevent vascular smooth muscle relaxation [52]. What is evident is 
that CFTR plays an important role in smooth muscle contraction and its compromised 
action in CF patients is likely to be the reason for lack of vascular and other smooth 
muscle relaxation. 
The action of CTFTR in the enterocyte may be a by-product and not a matter 
of central concern in the pathology of cystic fi brosis
One interpretation of these ϐindings is that vascular smooth muscle is less able to 
undergo relaxation in CF sufferers. This could be due to refractoriness to dilatatory 
stimuli but also there is the possibility that larger circular smooth muscle mass does 
not allow vasodilatation. This interpretation ϐits in with the ϐindings in CF knockout 
mice of their refractoriness to cholera and their lesser ability to respond to intestinal 
challenge by bacterial enterotoxins. If the smooth muscle of CF arteries cannot easily 
achieve a state of vasodilatation, then this would severely reduce ϐluid secretion into 
the lumen, as has been shown by the work of Gabriel and colleagues [32]. In addition, 
a case can also made for the origin of the increased short-circuit after enterotoxin 
derangement being in the intestinal vasculature [30]. If the vasculature in CF cannot 
adequately vasodilate, then the stimulus for provoking an increase in short-circuit 
current would be severely muted [31], not necessarily absent but attenuated since 
active neurogenic vasodilatation might not occur but some expansion of the internal 
diameter through physical forces might still be possible even if the arterioles were 
thicker than normal and had less compliance.
The concept of ϐluid secretion and also the signal for changing short-circuit current 
originating in the vascular smooth muscle harmonises with work on the effect of 
PGE
1
 and misoprostol on intestinal function. In isolated T
84
 cells grown to conϐluence, 
prostaglandin E
1
 alters the pattern of ion movement and enhances bidirectional 
chloride ion permeation but more particularly towards the luminal bathing ϐluid [62]. 
Evidently there must be prostaglandin receptors in or on the cells and there is an 
undoubted in vitro action on ion transport by the cells with signiϐicant increases in 
short-circuit current. 
In humans, in vivo, the PGE
1
 analogue, misoprostol, changes ϐluid absorption to 
secretion and changes the measured potential difference [63]. In cystic ϐibrotic subjects, 
misoprostol reduces net absorption to zero but there is neither net secretion nor a 
change in potential difference. The conventional explanation is that PGE
1
 is secretory 
and the change in electrical events should reϐlect this but for the dysfunctional chloride 
channel in CF heterozygotes. However, the data also ϐit well with the idea that an anti-
absorptive action of PGE
1
 stops ϐluid absorption i.e. reduces it to zero and a separate 
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vasodilator effect on arterioles causes’ secretion. In CF, the anti-absorptive action is 
present and reduces net absorption to zero. Note that if CF protects against secretion 
and this action is via the chloride channel, there is no particular reason why ϐluid 
absorption should be zero; it should prevent PGE
1
 from having any effect at all and 
net absorption should arguably be close to control values and yet this does not occur. 
The alternative explanation that CF arterioles cannot vasodilate offers the explanation 
that the anti-absorptive effect of PGE
1
 continues but CF arterioles cannot dilate and 
therefore there is no net secretory action of PGE
1
 on CF intestine. Similarly, there are 
no changes in electrical potential difference because there are normally initiated by 
a change in interstitial volume causing vasodilatation but the CF vasculature dilates 
poorly, if at all, and therefore there is no change in electrical signal.
An alternative explanation for the reduced ability in CF to secrete after cholera 
challenge and to mount a short-circuit current response after STa could be that the 
smooth muscle is overdeveloped in CF and vasodilatation is very muted.
Recent evidence for smooth muscle involvement in CF from clinical trials 
with lumacaftor and ivacaftor
 The concept of smooth muscle physiology being a cause of cystic ϐibrotic dysfunction 
as indicated here, has received support from the recent introduction of new drugs, 
ivacaftor and lumacaftor, that facilitate introduction of CFTR into membranes or 
repair the existing CFTR. A recent review of the effects of these drugs [64] has drawn 
attention to the improvement in the forced expiratory volume after one second, FEV1, 
in patients with CF but with caveats about the type of mutation that the patient has. 
In patients with the G551-D mutation, ivacaftor gave on average a 10% increase in 
respiratory function based on forced expiration measurements [65,66], not conϐirmed 
in patients having class 2 mutations [67]. Where there is no insertion of CFTR into the 
cell membrane, it seems that these new drugs are less impressive. In the appropriate 
mutation, improvements in FEV1 of the order of 15% have been detected [68]. 
Importantly for the smooth muscle concept detailed here, non-invasive pulse wave 
velocity measurements were lower after ivacaftor treatment, indicative of vascular 
smooth muscle relaxation. In addition, there was increased airways distensibility, both 
events showing a general dysfunction in this mutation of smooth muscle physiology. 
The responding G551-D mutation is a small fraction of the CF pool. However, there 
may be an underlying smooth muscle abnormality in F508 deletions that cannot be 
treated by these newer drugs but might be by drugs that facilitate insertion of CFTR 
channels into smooth muscle cell membrane.
Recent clinical trials have indicated that improvement in forced expiratory 
volume is seen in particular CF deletions and points to smooth muscle 
involvement in CF
Synopsis
1. Secretion in the small intestine may not be mediated by chloride ion secretion by 
the enterocyte but by vasodilatation of intestinal arterioles raising intracapillary 
and therefore interstitial ϐluid pressure and extruding ϐluid by physical force 
into the intestine in accordance with Starlings equation for ϐluid movement 
across the capillary. If a valid model, then this makes deleterious mutation of the 
enterocyte chloride ion channel irrelevant to the concept of selective advantage 
but it may show instead that net ϐluid absorption is hindered by a defective 
chloride ion channel.
2. The common occurrence of CFTR in smooth muscle cells as well as in the 
enterocytes makes it possible that agents that affect ϐluid movement are also 
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acting on the vascular smooth muscle. There is evidence that CF smooth muscle 
does not undergo relaxation. It is this aspect of CF pathology that may explain 
the selective advantage but it is evident that failure to secrete ϐluid in response 
to bacterial challenge may be just an associated phenomenon. Important 
aspects of CF pathology may not be well illuminated by inferences drawn from 
the enterocyte secretion model.
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